Works matching AU Itobayashi, Ei

Results: 86
    1

    Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study.

    Published in:
    Liver International, 2025, v. 45, n. 7, p. 1, doi. 10.1111/liv.70192
    By:
    • Hatanaka, Takeshi;
    • Yata, Yutaka;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Kakizaki, Satoru;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Koshiyama, Yuichi;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi
    Publication type:
    Article
    2

    Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective Analysis.

    Published in:
    Oncology, 2025, v. 103, n. 2, p. 94, doi. 10.1159/000541002
    By:
    • Hatanaka, Takeshi;
    • Saito, Naoto;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Ishikawa, Toru;
    • Toyoda, Hidenori;
    • Kawata, Kazuhito;
    • Naganuma, Atsushi;
    • Yata, Yutaka;
    • Ohama, Hideko;
    • Matono, Tomomitsu;
    • Tada, Fujimasa;
    • Nouso, Kazuhiro;
    • Morishita, Asahiro;
    • Tsutsui, Akemi
    Publication type:
    Article
    3

    Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.

    Published in:
    Oncology, 2023, v. 101, n. 10, p. 624, doi. 10.1159/000531316
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    4

    Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.

    Published in:
    Oncology, 2023, v. 101, n. 9, p. 542, doi. 10.1159/000530028
    By:
    • Ohama, Hideko;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    5

    Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.

    Published in:
    Oncology, 2023, v. 101, n. 4, p. 270, doi. 10.1159/000527676
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Hirooka, Masashi;
    • Takaguchi, Koichi;
    • Atsukawa, Masanori;
    • Fukunishi, Shinya;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Ishikawa, Toru;
    • Yasuda, Satoshi;
    • Ogawa, Chikara;
    • Toyoda, Hidenori;
    • Hatanaka, Takeshi;
    • Nishimura, Takashi;
    • Kakizaki, Satoru
    Publication type:
    Article
    6

    Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2022, v. 100, n. 12, p. 645, doi. 10.1159/000526521
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    7

    Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.

    Published in:
    Oncology, 2022, v. 100, n. 2, p. 65, doi. 10.1159/000520292
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Kariyama, Kazuya;
    • Toyoda, Hidenori;
    • Yasuda, Satoshi;
    • Tsuji, Kunihiko;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Naganuma, Atsushi;
    • Ishikawa, Toru;
    • Tada, Toshifumi;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Tanaka, Takaaki;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Imai, Michitaka;
    • Nakamura, Shinichiro
    Publication type:
    Article
    8

    Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.

    Published in:
    Oncology, 2021, v. 99, n. 8, p. 518, doi. 10.1159/000515896
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Michitaka, Kojiro;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Fukunishi, Shinya;
    • Ohama, Hideko;
    • Kawata, Kazuhito
    Publication type:
    Article
    9

    Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2020, v. 98, n. 5, p. 295, doi. 10.1159/000506293
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Kawata, Kazuhito;
    • Toyoda, Hidenori;
    • Ohama, Hideko;
    • Tsutsui, Akemi;
    • Itokawa, Norio
    Publication type:
    Article
    10

    Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2019, v. 97, n. 6, p. 334, doi. 10.1159/000502095
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Itokawa, Norio;
    • Hayama, Korenobu
    Publication type:
    Article
    11

    Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2019, v. 97, n. 5, p. 277, doi. 10.1159/000501281
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Itokawa, Norio;
    • Hayama, Korenobu
    Publication type:
    Article
    12
    13

    Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma.

    Published in:
    Liver Cancer International, 2023, v. 4, n. 3, p. 101, doi. 10.1002/lci2.74
    By:
    • Nouso, Kazuhiro;
    • Shiota, Shohei;
    • Fujita, Rio;
    • Wakuta, Akiko;
    • Kariyama, Kazuya;
    • Hiraoka, Atsushi;
    • Atsukawa, Masanori;
    • Tani, Joji;
    • Tada, Toshifumi;
    • Matsuo, Yu;
    • Nakamura, Shinichiro;
    • Tajiri, Kazuto;
    • Kaibori, Masaki;
    • Hirooka, Masashi;
    • Itobayashi, Ei;
    • Kakizaki, Satoru;
    • Naganuma, Atsushi;
    • Ishikawa, Toru;
    • Hatanaka, Takeshi;
    • Fukunishi, Shinya
    Publication type:
    Article
    14

    Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy.

    Published in:
    Liver Cancer (2235-1795), 2025, v. 14, n. 1, p. 8, doi. 10.1159/000539380
    By:
    • Inoue, Masanori;
    • Ogasawara, Sadahisa;
    • Kobayashi, Kazufumi;
    • Okubo, Tomomi;
    • Itokawa, Norio;
    • Obu, Masamichi;
    • Fujimoto, Kentaro;
    • Unozawa, Hidemi;
    • Yumita, Sae;
    • Fujiwara, Kisako;
    • Nakagawa, Miyuki;
    • Kanzaki, Hiroaki;
    • Koroki, Keisuke;
    • Kiyono, Soichiro;
    • Nakamura, Masato;
    • Kanogawa, Naoya;
    • Kondo, Takayuki;
    • Nakamoto, Shingo;
    • Nagashima, Kengo;
    • Itobayashi, Ei
    Publication type:
    Article
    15

    Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality.

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 6, p. 565, doi. 10.1159/000530078
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Kariyama, Kazuya;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Naganuma, Atsushi;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Ohama, Hideko;
    • Tada, Fujimasa;
    • Nouso, Kazuhiro
    Publication type:
    Article
    16

    Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 209, doi. 10.1159/000527402
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    17

    Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

    Published in:
    Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 473, doi. 10.1159/000515552
    By:
    • Koroki, Keisuke;
    • Kanogawa, Naoya;
    • Maruta, Susumu;
    • Ogasawara, Sadahisa;
    • Iino, Yotaro;
    • Obu, Masamichi;
    • Okubo, Tomomi;
    • Itokawa, Norio;
    • Maeda, Takahiro;
    • Inoue, Masanori;
    • Haga, Yuki;
    • Seki, Atsuyoshi;
    • Okabe, Shinichiro;
    • Koma, Yoshihiro;
    • Azemoto, Ryosaku;
    • Atsukawa, Masanori;
    • Itobayashi, Ei;
    • Ito, Kenji;
    • Sugiura, Nobuyuki;
    • Mizumoto, Hideaki
    Publication type:
    Article
    18

    Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

    Published in:
    Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 473, doi. 10.1159/000515552
    By:
    • Koroki, Keisuke;
    • Kanogawa, Naoya;
    • Maruta, Susumu;
    • Ogasawara, Sadahisa;
    • Iino, Yotaro;
    • Obu, Masamichi;
    • Okubo, Tomomi;
    • Itokawa, Norio;
    • Maeda, Takahiro;
    • Inoue, Masanori;
    • Haga, Yuki;
    • Seki, Atsuyoshi;
    • Okabe, Shinichiro;
    • Koma, Yoshihiro;
    • Azemoto, Ryosaku;
    • Atsukawa, Masanori;
    • Itobayashi, Ei;
    • Ito, Kenji;
    • Sugiura, Nobuyuki;
    • Mizumoto, Hideaki
    Publication type:
    Article
    19

    What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

    Published in:
    Liver Cancer (2235-1795), 2021, v. 10, n. 2, p. 115, doi. 10.1159/000513355
    By:
    • Atsushi Hiraoka;
    • Takashi Kumada;
    • Toshifumi Tada;
    • Kazuya Kariyama;
    • Joji Tani;
    • Shinya Fukunishi;
    • Masanori Atsukawa;
    • Masashi Hirooka;
    • Kunihiko Tsuji;
    • Toru Ishikawa;
    • Koichi Takaguchi;
    • Ei Itobayashi;
    • Kazuto Tajiri;
    • Noritomo Shimada;
    • Hiroshi Shibata;
    • Hironori Ochi;
    • Kazuhito Kawata;
    • Satoshi Yasuda;
    • Hidenori Toyoda;
    • Hideko Ohama
    Publication type:
    Article
    20

    EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 6, p. 734, doi. 10.1159/000508971
    By:
    • Kariyama, Kazuya;
    • Nouso, Kazuhiro;
    • Hiraoka, Atsushi;
    • Wakuta, Akiko;
    • Oonishi, Ayano;
    • Kuzuya, Teiji;
    • Toyoda, Hidenori;
    • Tada, Toshifumi;
    • Tsuji, Kunihiko;
    • Itobayashi, Ei;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Tsutsui, Akemi;
    • Shimada, Noritomo;
    • Kudo, Masatoshi;
    • Kumada, Takashi
    Publication type:
    Article
    21

    Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 4, p. 382, doi. 10.1159/000507022
    By:
    • Maruta, Susumu;
    • Ogasawara, Sadahisa;
    • Ooka, Yoshihiko;
    • Obu, Masamichi;
    • Inoue, Masanori;
    • Itokawa, Norio;
    • Haga, Yuki;
    • Seki, Atsuyoshi;
    • Okabe, Shinichiro;
    • Azemoto, Ryosaku;
    • Itobayashi, Ei;
    • Atsukawa, Masanori;
    • Sugiura, Nobuyuki;
    • Mizumoto, Hideaki;
    • Koroki, Keisuke;
    • Kanayama, Kengo;
    • Kanzaki, Hiroaki;
    • Kobayashi, Kazufumi;
    • Kiyono, Soichiro;
    • Nakamura, Masato
    Publication type:
    Article
    22

    Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 1, p. 73, doi. 10.1159/000503031
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Yokohama, Keisuke;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya
    Publication type:
    Article
    23
    24

    Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 10, p. 1361, doi. 10.1111/apt.18237
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article
    25

    Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 2, p. 233, doi. 10.1111/apt.18037
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Nishikawa, Hiroki;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Koshiyama, Yuichi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Kawata, Kazuhito
    Publication type:
    Article
    26
    27

    Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 8, p. 3719, doi. 10.1002/cam4.2241
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Itokawa, Norio;
    • Hayama, Korenobu
    Publication type:
    Article
    28

    Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 1, p. 137, doi. 10.1002/cam4.1909
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Kariyama, Kazuya;
    • Takaguchi, Koichi;
    • Atsukawa, Masanori;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Tajiri, Kazuto;
    • Hirooka, Masashi;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ishikawa, Toru;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Itokawa, Norio;
    • Imai, Michitaka;
    • Joko, Kouji
    Publication type:
    Article
    29

    Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.

    Published in:
    Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-024-78539-4
    By:
    • Ohama, Hideko;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    30

    Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis.

    Published in:
    Therapeutic Apheresis & Dialysis, 2017, v. 21, n. 5, p. 465, doi. 10.1111/1744-9987.12563
    By:
    • Toyoda, Hidenori;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Michitaka, Kojiro;
    • Takaguchi, Koichi;
    • Tsuji, Kunihiko;
    • Itobayashi, Ei;
    • Takizawa, Daichi;
    • Hirooka, Masashi;
    • Koizumi, Yohei;
    • Ochi, Hironori;
    • Joko, Koji;
    • Kisaka, Yoshiyasu;
    • Shimizu, Yuko;
    • Tajiri, Kazuto;
    • Tani, Joji;
    • Taniguchi, Tatsuya;
    • Toshimori, Akiko;
    • Fujioka, Shinichi;
    • Kumada, Takashi
    Publication type:
    Article
    31

    Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.

    Published in:
    Gastroenterology Report, 2021, v. 9, n. 2, p. 133, doi. 10.1093/gastro/goaa042
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Ogawa, Chikara;
    • Tani, Joji;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Kawata, Kazuhito;
    • Toyoda, Hidenori;
    • Ohama, Hideko
    Publication type:
    Article
    32

    Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab–Treated HCC.

    Published in:
    Journal of Gastroenterology & Hepatology, 2025, v. 40, n. 4, p. 949, doi. 10.1111/jgh.16884
    By:
    • Matono, Tomomitsu;
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Nishikawa, Hiroki;
    • Tanaka, Kazunari;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Koshiyama, Yuichi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Hatanaka, Takeshi
    Publication type:
    Article
    33

    Reliable Performance of mALBI Grade‐Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First‐Line Treatment: Comparative Analysis of 13 Risk Models.

    Published in:
    Journal of Gastroenterology & Hepatology, 2025, v. 40, n. 4, p. 930, doi. 10.1111/jgh.16871
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article
    34

    Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents.

    Published in:
    Journal of Gastroenterology & Hepatology, 2024, v. 39, n. 7, p. 1394, doi. 10.1111/jgh.16553
    By:
    • Ohama, Hideko;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Toyoda, Hidenori;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Naganuma, Atsushi;
    • Tada, Fujimasa;
    • Tanaka, Hironori;
    • Nakamura, Shinichiro;
    • Nouso, Kazuhiro;
    • Tanaka, Kazunari;
    • Kumada, Takashi
    Publication type:
    Article
    35

    Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.

    Published in:
    Journal of Gastroenterology & Hepatology, 2024, v. 39, n. 5, p. 949, doi. 10.1111/jgh.16494
    By:
    • Toyoda, Hidenori;
    • Tada, Toshifumi;
    • Uojima, Haruki;
    • Nozaki, Akito;
    • Chuma, Makoto;
    • Takaguchi, Koichi;
    • Hiraoka, Atsushi;
    • Abe, Hiroshi;
    • Itobayashi, Ei;
    • Matsuura, Kentaro;
    • Atsukawa, Masanori;
    • Watanabe, Tsunamasa;
    • Shimada, Noritomo;
    • Nakamuta, Makoto;
    • Kojima, Motoyuki;
    • Tsuji, Kunihiko;
    • Mikami, Shigeru;
    • Ishikawa, Toru;
    • Yasuda, Satoshi;
    • Tsutsui, Akemi
    Publication type:
    Article
    36

    Impact of first‐line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

    Published in:
    Journal of Gastroenterology & Hepatology, 2023, v. 38, n. 8, p. 1389, doi. 10.1111/jgh.16225
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    37

    Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.

    Published in:
    Journal of Gastroenterology & Hepatology, 2021, v. 36, n. 7, p. 1812, doi. 10.1111/jgh.15336
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Kariyama, Kazuya;
    • Tada, Toshifumi;
    • Tani, Joji;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Kawata, Kazuhito;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ohama, Hideko
    Publication type:
    Article
    38
    39

    Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma.

    Published in:
    Cancers, 2019, v. 11, n. 2, p. 203, doi. 10.3390/cancers11020203
    By:
    • Kariyama, Kazuya;
    • Nouso, Kazuhiro;
    • Toyoda, Hidenori;
    • Tada, Toshifumi;
    • Hiraoka, Atsushi;
    • Tsuji, Kunihiko;
    • Itobayashi, Ei;
    • Ishikawa, Toru;
    • Wakuta, Akiko;
    • Oonishi, Ayano;
    • Kumada, Takashi;
    • Kudo, Masatoshi
    Publication type:
    Article
    40

    Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).

    Published in:
    Investigational New Drugs, 2024, v. 42, n. 4, p. 394, doi. 10.1007/s10637-024-01441-3
    By:
    • Kobayashi, Kazufumi;
    • Ogasawara, Sadahisa;
    • Itobayashi, Ei;
    • Okubo, Tomomi;
    • Itokawa, Norio;
    • Nakamura, Kazuyoshi;
    • Moriguchi, Michihisa;
    • Watanabe, Shunji;
    • Ikeda, Masafumi;
    • Kuroda, Hidekatsu;
    • Kawaoka, Tomokazu;
    • Hiraoka, Atsushi;
    • Yasui, Yutaka;
    • Kuzuya, Teiji;
    • Sato, Rui;
    • Kanzaki, Hiroaki;
    • Koroki, Keisuke;
    • Inoue, Masanori;
    • Nakamura, Masato;
    • Kiyono, Soichiro
    Publication type:
    Article
    41

    Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 1, p. 172, doi. 10.1007/s10637-019-00801-8
    By:
    • Ogasawara, Sadahisa;
    • Ooka, Yoshihiko;
    • Itokawa, Norio;
    • Inoue, Masanori;
    • Okabe, Shinichiro;
    • Seki, Atsuyoshi;
    • Haga, Yuki;
    • Obu, Masamichi;
    • Atsukawa, Masanori;
    • Itobayashi, Ei;
    • Mizumoto, Hideaki;
    • Sugiura, Nobuyuki;
    • Azemoto, Ryosaku;
    • Kanayama, Kengo;
    • Kanzaki, Hiroaki;
    • Maruta, Susumu;
    • Maeda, Takahiro;
    • Kusakabe, Yuko;
    • Yokoyama, Masayuki;
    • Kobayashi, Kazufumi
    Publication type:
    Article
    42
    43

    Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.

    Published in:
    Cancer Medicine, 2025, v. 14, n. 2, p. 1, doi. 10.1002/cam4.70618
    By:
    • Naganuma, Atsushi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hatanaka, Takeshi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article
    44

    Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 24, p. 21680, doi. 10.1002/cam4.6726
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Yokohama, Keisuke;
    • Nishikawa, Hiroki
    Publication type:
    Article
    45

    Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 17, p. 17849, doi. 10.1002/cam4.6416
    By:
    • Nouso, Kazuhiro;
    • Shiota, Shohei;
    • Fujita, Rio;
    • Wakuta, Akiko;
    • Kariyama, Kazuya;
    • Hiraoka, Atsushi;
    • Atsukawa, Masanori;
    • Tani, Joji;
    • Tada, Toshifumi;
    • Nakamura, Shinichiro;
    • Tajiri, Kazuto;
    • Kaibori, Masaki;
    • Hirooka, Masashi;
    • Itobayashi, Ei;
    • Kakizaki, Satoru;
    • Naganuma, Atsushi;
    • Ishikawa, Toru;
    • Hatanaka, Takeshi;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko
    Publication type:
    Article
    46

    Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 7, p. 7772, doi. 10.1002/cam4.5535
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    47

    New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 6, p. 6980, doi. 10.1002/cam4.5495
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Hirooka, Masashi;
    • Takaguchi, Koichi;
    • Atsukawa, Masanori;
    • Fukunishi, Shinya;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Ishikawa, Toru;
    • Yasuda, Satoshi;
    • Ogawa, Chikara;
    • Toyoda, Hidenori;
    • Hatanaka, Takeshi;
    • Nishimura, Takashi;
    • Kakizaki, Satoru
    Publication type:
    Article
    48

    Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 5, p. 5293, doi. 10.1002/cam4.5337
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Shimada, Noritomo
    Publication type:
    Article
    49

    The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 4, p. 4259, doi. 10.1002/cam4.5294
    By:
    • Hatanaka, Takeshi;
    • Naganuma, Atsushi;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Shimada, Noritomo
    Publication type:
    Article
    50

    Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 1, p. 325, doi. 10.1002/cam4.4854
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article